• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Patients with hematological malignancies and concomitant COVID-19 have worse health outcomes

byNeel MistryandTeddy Guo
December 23, 2020
in Chronic Disease, Infectious Disease, Oncology, Public Health
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Older age, progressive disease status, diagnosis of acute myeloid leukemia, non-Hodgkin lymphoma, or plasma cell neoplasms, and severe or critical COVID-19 at admission were predictive of worse overall survival.

2. Compared to the general population with COVID-19, the mortality rate was four times higher among COVID-positive patients with concomitant hematological malignancies.

Evidence Rating Level: 2 (Good) 

Study Rundown: Few studies have explored health outcomes in patients with hematological malignancies and the novel SARS-CoV-2 infection. This multicentre, retrospective cohort study assessed the clinical trajectory of adult hematology patients with laboratory-confirmed COVID-19 In Italy. The primary outcome for this study was patient mortality and predictive parameters of mortality, including biochemical parameters (hemoglobin, hematocrit, platelets, leucocytes, lymphocytes, clotting tests, serum lactate dehydrogenase, and C-reactive protein), hematological malignancy characteristics, and COVID-19 severity. In comparison to the general Italian population with COVID-19 and patients with hematological malignancies without COVID-19, the mortality rate was significantly elevated in patients with concomitant COVID-19 and hematologic malignancies. Additionally, severe or critical COVID-19 diagnoses were more frequent in patients with hematological malignancies. This study was limited by a retrospective design and lack of generalizability. Asymptomatic patients, or those who were not tested for SARS-CoV-2 infection, were excluded from this study leading to a lower mortality rate. Nevertheless, this study reported the largest series of patients with hematological malignancies and COVID-19 to date.

Click to read the study in The Lancet Haematology

Relevant Reading: Screening Strategies for COVID-19 in Patients with Hematologic Malignancies

RELATED REPORTS

Hereditary erythrocytosis is associated with a fetal-like EPO isoform

Reduced-dose apixaban noninferior to full dose for cancer-associated thrombosis

Analysis of clinical outcomes utilizing ultrasound-assisted catheter-directed thrombolysis for pulmonary embolism

In-depth [retrospective cohort]: This multicentre, retrospective study included 536 patients (≥18 years old) from 66 Italian hospitals enrolled between February 25, 2020 to May 18, 2020. All participants were diagnosed with a World Health Organization-defined hematological malignancy and confirmed COVID-19. The median length of hospital stay was 20 days (IQR 10-34 days, range 1-98 days).

Compared to the general population with COVID-19, the standardized mortality ratio was 2.04 (95% CI 1.77-2.34) in the study cohort and 3.72 (95% CI 2.86-4.64) among patients younger than 70 years of age. Likewise, patients with hematological malignancies and confirmed-SARS-CoV-2 infection had a standardized mortality ratio of 41.3 (95% CI 38.1-44.9) compared to non-COVID-19 cohorts with hematologic malignancies. Among 451 hospitalized patients, the most common symptoms at the time of admission included fever (75%), dyspnea (51%), cough (45%), and malaise (39%). Of the 536 individuals enrolled in this study, 194 (36%) had severe COVID-19 and 74 (14%) had critical COVID-19. By June 22, 2020, 37% of the enrolled patients had died, with a mortality rate of 153.2 deaths (95% CI 129.7-172.1) per 10 000 person-days. Factors associated with poor health outcomes included older age (Hazard ratio [HR] 1.03, 95% CI 1.01-1.05); progressive disease status (HR 2.10, 95% CI 1.41-3.12); diagnosis of acute myeloid leukemia (HR 3.49, 95% CI 1.56-7.81), indolent non-Hodgkin lymphoma (HR 2.19, 95% CI 1.07-4.48), aggressive non-Hodgkin lymphoma (HR 2.56, 95% CI 1.34-4.89), or plasma cell neoplasms (HR 2.48, 95% CI 1.31-4.69), and severe or critical COVID-19 (HR 4.08, 95% CI 2.73-6.09). Among 451 inpatients, 295 (65%) were treated with hydroxychloroquine (of whom 99 [34%] died), 188 (42%) with antiviral agents (of whom 71 [38%] died), 135 (30%) with heparins (of whom 46 [34%] died), and 40 (9%) with tocilizumab (of whom 16 [40%] died). Overall, findings of this retrospective cohort study highlight the poor health outcomes among patients with concomitant hematological malignancies and confirmed-COVID-19 diagnosis.

Image: PD

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: acute myeloid leukemiaacute myeloid leukemia (AML)hematologic malignancyhematologyHodgkin LymphomaNon-Hodgkin Lymphoma
Previous Post

Allogeneic anti-CD19 T cell therapy shows a manageable safety profile in pediatric and adult patients with high risk B-cell acute lymphoblastic leukemia

Next Post

#VisualAbstract: Enteral water-soluble vitamin A in extremely preterm infants does not reduce severity of bronchopulmonary dysplasia

RelatedReports

New genetic link in pulmonary arterial hypertension holds therapeutic promise
Chronic Disease

Hereditary erythrocytosis is associated with a fetal-like EPO isoform

June 2, 2025
Thrombophilia-associated stillbirth risk appears limited to factor V Leiden
Hematology

Reduced-dose apixaban noninferior to full dose for cancer-associated thrombosis

May 20, 2025
Quick Take: Hospital volume and outcomes for acute pulmonary embolism
Cardiology

Analysis of clinical outcomes utilizing ultrasound-assisted catheter-directed thrombolysis for pulmonary embolism

April 30, 2025
Thrombophilia-associated stillbirth risk appears limited to factor V Leiden
Chronic Disease

Self reported physical activity not significantly different across different severities of hemophilia

April 4, 2025
Next Post
#VisualAbstract: Adjunctive methylprednisolone treatment for hepatitis B acute-on-chronic liver failure associated with increased survival

#VisualAbstract: Enteral water-soluble vitamin A in extremely preterm infants does not reduce severity of bronchopulmonary dysplasia

#VisualAbstract: Low plasma ctDNA may be predictive of better survival outcomes in patients with melanoma receiving first-line immune checkpoint inhibitors

#VisualAbstract: Low plasma ctDNA may be predictive of better survival outcomes in patients with melanoma receiving first-line immune checkpoint inhibitors

#VisualAbstract CASSIOPEIA Part 1: Bortezomib, Thalidomide, and Dexamethasone with Daratumumab (D-VTd) May Improve Quality of Life Post-Consolidation in Newly Diagnosed, Transplantation-Eligible Multiple Myeloma (MM) Patients

#VisualAbstract CASSIOPEIA Part 1: Bortezomib, Thalidomide, and Dexamethasone with Daratumumab (D-VTd) May Improve Quality of Life Post-Consolidation in Newly Diagnosed, Transplantation-Eligible Multiple Myeloma (MM) Patients

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Artificial intelligence based clinical decision systems are safe and effective for diabetes management
  • Epic Launchpad propels generative-AI into everyday hospital routines
  • #VisualAbstract: Routine Cerebral Embolic Protection Did Not Reduce Stroke Incidence during Transcatheter Aortic-Valve Implantation
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.